Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept

Annals of the Rheumatic Diseases

Volumn 65, Issue 12, 2006, Pages 1649-1652

  Goldman, J A ^a   Xia, H A ^b   White, B ^b   Paulus, H ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL SCHOOL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33751278529     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.047266     Document Type: Article

References (9)

1. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990;33:477-84.
2. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
3. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
4. Wolfe F, Michaud K, Pincus T. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum 2004;50:3296-305.
5. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
6. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
7. DAS-SCORE. NL. Home of the DAS (Disease Activity Score in rheumatoid arthritis). http://www.das-score.nl/www.das-score.nl/index.html (accessed 16 July 2005).
8. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
9. van Riel PL, van Gestel AM. Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis? Arthritis Rheum 2001;44:1719-21.